Amgen Inc.'s PCSK9 inhibitor Repatha (evolocumab) demonstrated ability to reduce plaque build-up in the GLAGOV imaging study, which could pave the way for an additional indication, but it's unclear whether this latest success will help the cholesterol drug where it needs it most – with payers.
Repatha and Sanofi/Regeneron Pharmaceuticals Inc.'s competing Praluent (alirocumab) have struggled to break into the market as payers have...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
